Understanding cancer analysis, one honest story at a time
Plain-language lessons from real, anonymized molecular analyses — what the data said, what helped, and what every patient deserves to know before the next decision.
Does depending on AI erode our thinking? A mathematical look at a quiet risk
Our preprint builds a mathematical framework for how critical thinking may erode — across generations — as humans lean on AI language models for cognitive work. From the team that builds AI tools: why we study our own tools' risks.
AI that measures a baby's head in the womb: ELLIPSE-YOLO explained simply
Fetal head circumference is one of the most important measurements in pregnancy — and it is usually traced by hand. Our published ELLIPSE-YOLO system automates it: 100% detection on the HC18 benchmark, running on an ordinary GPU. Here is how it works.
Why does psoriasis always come back — and could it be cleared for good? A computer model's answer
Psoriasis returns after treatment because memory immune cells stay camped in the skin. Our published mathematical model screened 5,757 drug combinations and predicts a five-part protocol with 85–87% permanent clearance — in the computer. Here is the idea, in plain words.
We tested 190,000 drug combinations for breast cancer in a computer. Here is what came out
Our published framework scored ~190,000 four-drug combinations across three breast cancer subtypes and five stages — balancing efficacy, toxicity, drug interactions and cost. The surprises: a cheap anti-parasitic drug kept winning, and heavily pretreated disease is where options run out.
Can Spirulina and Moringa help chemotherapy work better in pancreatic cancer? What our research found
Our published computational study found that compounds from Spirulina and Moringa may re-sensitize resistant pancreatic cancer to FOLFIRINOX chemotherapy — with a predicted 87.9% cell death versus 83.3% for chemo alone. Here is what that means, and what it does not mean.
What does 5-year survival rate actually mean? Cancer statistics explained
A 5-year survival rate is a statistic about past patients — not a prediction about you. What median survival, five-year rates and 'cure' really mean, and why today's numbers run years behind today's medicine.
What is a molecular tumour board — and how do I ask for one?
A molecular tumour board is a panel of specialists that matches your tumour's genetic faults to therapies and trials. Who sits on it, what it needs from you, and exactly how to request one.
How to get a second opinion for cancer — without offending your doctor
Second opinions change the diagnosis or the plan in a meaningful share of cancer cases, and good oncologists expect them. What to collect, what to ask, and how to do it quickly and respectfully.
Clinical trials for cancer: phases, myths, and how to actually find one
Clinical trials are how every standard cancer treatment earned its place — and joining one is often the only route to tomorrow's drug today. Phases 1–3 explained, myths corrected, search steps included.
What is a PET scan? SUV, Deauville scores and results explained simply
A PET scan shows where the body is burning sugar fastest — which is usually where active cancer is. What SUV numbers mean, what a Deauville score is, and why 'hot spots' aren't always cancer.
Chemotherapy vs targeted therapy vs immunotherapy: what's the difference?
Three families of cancer drugs work in three different ways: chemotherapy attacks dividing cells, targeted therapy blocks a specific fault, immunotherapy unleashes your immune system. A plain comparison.
What is genomic testing for cancer? NGS, mutations and 'targetable' explained
Genomic testing reads your tumor's DNA to find the faults driving it — and sometimes a drug aimed at exactly that fault. What NGS panels report, what 'actionable mutation' means, and what to ask.
Tumor markers explained: what cancer blood tests can and cannot tell you
CEA, CA 19-9, PSA, LDH — tumor markers are useful for tracking treatment, but poor at diagnosing cancer. What the numbers mean, why they rise without cancer, and the right questions to ask.
Cancer staging explained: what stages 0 to 4 and TNM really mean
Stage describes how far a cancer has spread — not how fast it grows or how treatable it is. A plain-language guide to TNM, stages 0–4, and the difference between stage and grade.
How to read a biopsy report — a plain-language guide
A biopsy report answers three questions: is it cancer, what type, and how aggressive. Here is what each section means — grade, margins, immunohistochemistry — in words anyone can follow.
Half the dose, half the chance? What dose intensity research says about aggressive lymphoma
Our published case analysis scored a real first-line treatment at 67/100 because it was given at roughly half dose — while a full-dose plan available on the same day scored 90/100. In curable aggressive lymphoma, the dose is the cure.
Why cancer treatment fails even when doctors know what to do — new research
Our published analysis of an aggressive lymphoma case found the information gap was exactly zero — every fact needed for a better outcome was already in the records. The failures were delays and unexecuted plans, worth a simulated 16.4 months of survival.
What is OmniSynx? The published research behind our cancer analysis platform
OmniSynx is a peer-reviewable, published framework that analyses cancer treatment journeys — every fact traced to a page in the patient's own records, every calculation reproducible. Here is what our research found, in plain words.
Your medical records are evidence — keep every page
An archive of 293 documents held one family's whole story — but more than half were scans no computer could read. What we found in them changed the entire conclusion of the analysis.
Five questions to ask before your first chemotherapy cycle
You do not need to be a doctor to change the course of your treatment. Five plain questions — drawn from real case analyses — that every patient has the right to ask before treatment begins.
When your cancer has two faults at once — attack both together
A rare bile-duct cancer carried two drug-targetable faults at the same time. The patient lived roughly three times the average — and the analysis shows where even more good time could have come from.
Why the full dose matters in aggressive lymphoma
In fast-growing lymphoma, the dose is the cure. The story of one young patient's records shows why starting at half strength — however cautious it feels — can cost the one chance standard treatment offers.
How a computer helps choose cancer drug combinations — explained simply
Cancers escape treatment through predictable exit routes. Our simulation scores hundreds of drug combinations by how many exits they cover at once — here is how that works, in plain words.
Open a ticket, attach your reports, and our analysis team will explain what your data says — in plain language.
Ask us about your reports